하버드 바이오사이언스HBIO 주가

Lensar Appoints Michael A. Rossi As Interim CFO Effective May 29, 2026

On May 25, 2026, the Board of Directors (the "Board") of LENSAR, Inc. (the "Company") appointed Michael A. Rossi to serve as the Company's Interim Chief Financial Officer and principal financial officer, effective as of

[SD] SD — FORM SD

♻️ 재탕Harvard Bioscience, Inc. 2026 Q1 - Results - Earnings Call Presentation

2026-05-15. The following slide deck was published by Harvard Bioscience, Inc.

[SCHEDULE 13G/A] SCHEDULE 13G/A

Harvard Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026

Harvard Bioscience, Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported sales was USD 20.76 million compared to USD 21.77 million a...

Harvard Bioscience Inc (NASDAQ:HBIO) Q1 Results Show Revenue Miss Offsets Earnings Beat

Harvard Bioscience Q1 revenue miss of $20.8M triggers 12% stock drop, though adjusted loss of -$0.33/share beats estimates.

♻️ 재탕Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript

Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDTCompany ParticipantsJohn Duke - President, CEO & DirectorMark Frost - CFO,...

♻️ 재탕Transcript : Harvard Bioscience, Inc., Q1 2026 Earnings Call, May 12, 2026

Presentation Operator MessageOperator Good day, and welcome to the Q1 2026 Harvard Biosciences, Inc. Earnings Conference Call. [Operator Instructions] Please note, this call is being recorded. I...

♻️ 재탕Harvard Bioscience Q1 2026 Earnings Call Transcript

Harvard Bioscience : Q1 2026 Harvard Bioscience, Inc. Earnings Conference Call

NASDAQ: HBIO 1Q26 Earnings Presentation John Duke, President & CEO Mark Frost, CFO & Treasurer May 12, 2026 First Quarter Operating...